Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries (Q30230410)

11 June 2017

1 reference

title

Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries (English)

1 reference

11 June 2017

3

Philippe Mayaud

1 reference

11 June 2017

Peter G Smith

7

0 references

Joakim Dillner

series ordinal

5

object named as

Joakim Dillner

1 reference

11 June 2017

6

Jorma Paavonen

1 reference

11 June 2017

4

Ruanne Barnabas

1 reference

11 June 2017

Matti Lehtinen

1

1 reference

PubMed ID

16950012

11 June 2017

Rolando Herrero

series ordinal

2

1 reference

PubMed ID

16950012

11 June 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

11 June 2017

1 reference

11 June 2017

24 Suppl 3

1 reference

11 June 2017

S3/233-41

1 reference

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

11 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Role of herd immunity in determining the effect of vaccines against sexually transmitted disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Mumps and rubella eliminated from Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Study designs for evaluating different efficacy and effectiveness aspects of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Effectiveness of preventive human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through 1995

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

High incidence of cervical human papillomavirus infection in women during their first sexual relationship

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Familial risks in cervical cancer: is there a hereditary component?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Efficacy of preventive human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Chlamydia trachomatis infection as a risk factor for invasive cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

The theoretical population-level impact of a prophylactic human papilloma virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Person-time analysis of paired community intervention trials when the number of communities is small.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Global cancer statistics in the year 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.109

10.1016/J.VACCINE.2006.05.109

7 January 2021

Identifiers

DOI

1 reference

11 June 2017

1 reference

PubMed ID

16950012